Endonovo Therapeutics Inc has been on a fast rise over the past month moving up off its base at $0.01 on very significant volume. Investors have been bidding up the price of ENDV in recent days.
ENDV is on fire after the Company announced its initial plans and strategy for a national rollout of its SofPulse(R) targeted pulsed electromagnetic field (tPEMF) therapy device to hospitals throughout the United States. The Company has recently signed agreements with six master distributors and has hired approximately 40 sales associates. Endonovo’s plan is to have 300 sales representatives and be in the evaluation stage with 600 hospitals within the next 18 months. To support the national rollout, Endonovo has appointed Pfizer Alum Ken Snider as national sales manager and DevicePharm as marketing firm of record.
Alan Collier, Endonovo’s chief executive officer, stated, “After careful consideration and discussions, and in accordance with our internal budgets, we have reached the point at which we can confidently announce our national rollout plan and strategy. We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse(R) device supports our plans to be in hospitals throughout all 50 states by 2020. With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse(R) is a natural and safe replacement to opioids and a solution to this health crisis. Based on the current progress.”
Endonovo Therapeutics Inc (OTCMKTS: ENDV) bills itself as a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis.
Endonovo non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.
Earlier this month ENVD appointed Steven Levin, M.D., to its scientific advisory board. Dr. Levin will work with the Endonovo team to facilitate the introduction of SofPulse(R) to healthcare facilities and further develop the Electroceutical(TM) devices pipeline. Dr. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. Additionally, he is an assistant professor at Johns Hopkins School of Medicine, Department of Anesthesiology.
“Dr. Levin’s vast experience with novel therapies in the anesthesiology and pain management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,” said Alan Collier, CEO, Endonovo Therapeutics. “As a leader in the field of pain management, Steven will contribute valuable knowledge and expertise as we move our programs forward.”
Currently trading at a $10.5 million market valuation ENDV has $58k in the treasury, significant debt and reported revenues of $45k for the 3 months ended March, 30, 2019. ENDV is an exciting story in small caps: ENDV is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, already doing sales with a number of important distribution agreements in place. The Company continues developing a portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis.
Christopher Ferraris is a third-year student at Temple University in Philadelphia. Having already completed an Associates Degree in Psychology, Christopher is now finishing his Bachelor’s degree in Finance. In preparation for working in the financial sector, Christopher is writing financial content and analysis. Every day, Christopher works on articles regarding the following topics: finance, cryptocurrency and technology.